BeOne Medicines's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $3.25.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $10.01.
During the past 12 months, BeOne Medicines's average earnings per share (NRI) Growth Rate was 1825.00% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BeOne Medicines's EPS without NRI or its related term are showing as below:
During the past 13 years, BeOne Medicines's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 27.00% per year. The lowest was -198.90% per year. And the median was -60.00% per year.
ONC's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.6 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BeOne Medicines's EPS (Diluted) for the
three
months ended in Mar. 2026 was $1.95.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.29.
BeOne Medicines's EPS (Basic) for the
three
months ended in Mar. 2026 was $2.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.81.
BeOne Medicines (NAS:ONC) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BeOne Medicines EPS without NRI Related Terms
BeOne Medicines EPS without NRI Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs MRNA, RPRX, ROIV: EPS without NRI Comparison
For the Biotechnology subindustry, BeOne Medicines's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a EPS without NRI of $10.01 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #999999 out of 1167 companies in the Biotechnology industry.
Is BeOne Medicines' EPS without NRI too high?
BeOne Medicines' current EPS without NRI is $10.01. The Biotechnology industry median EPS without NRI is 16.60. BeOne Medicines' value of $10.01 is 39.7% below this industry median. Based on the distribution chart, BeOne Medicines ranks #999999 out of 1167 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EPS without NRI compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #999999 out of 1167 companies for EPS without NRI. This places BeOne Medicines in the lower half of its industry. The industry median EPS without NRI is 16.60. BeOne Medicines' value of $10.01 is 39.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.60, based on 1,167 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current EPS without NRI of $10.01 is 39.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current EPS without NRI is $10.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.20, compared to a current price of $297.65 — trading 18.9% below its estimated fair value. The current EPS without NRI is $10.01 and 39.7% below the Biotechnology industry median of 16.60. BeOne Medicines' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BeOne Medicines (ONC), the current EPS without NRI is $10.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $297.65 is trading 18.9% below its estimated GF Value™ of $367.20.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
EPS without NRI: $10.01
GF Value™: $367.20 vs. price of $297.65 (18.9% below fair value)
Industry Position: 39.7% below the Biotechnology median (#999999 of 1167)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score
Get the complete analysis for ONC
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
